Allogene Therapeutics, Inc. logo ALLO - Allogene Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 19
HOLD 10
SELL 1
STRONG
SELL 0
| PRICE TARGET: $6.43 DETAILS
HIGH: $9.00
LOW: $3.85
MEDIAN: $6.42
CONSENSUS: $6.43
UPSIDE: 199.07%

Stock News

Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation

Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation

Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in first-line large B-cell lymphoma, with a key readout in mid-2027. ALLO-329's early clinical signals in autoimmune disease, leveraging proprietary Dagger technology, set up a differentiated, scalable CAR-T platform with high-value optionality. ALLO demonstrates improving financial discipline, reducing quarterly net loss to $42.6M and extending cash runway into early 2029 following a $200.4M public offering.

Jul 04, 2026 06:10 AM • seekingalpha.com
Allogene Therapeutics Announces Planned CEO Succession

Allogene Therapeutics Announces Planned CEO Succession

SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Dr. David Chang, M.D., Ph.D., will transition from his role as President and Chief Executive Officer, effective June 30, 2026, following eight years of leadership that established Allogene as a leader in the development of off-the-shelf cell therapies. Dr. Chang will continue to serve on the Company's Board of Directors.

May 28, 2026 01:02 PM • globenewswire.com
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that regulatory authorities in South Korea and Australia have cleared the Company to expand its pivotal Phase 2 ALPHA3 study evaluating cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation treatment for patients with large B-cell lymphoma (LBCL).

Apr 21, 2026 04:30 AM • globenewswire.com
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, today announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 17-22, 2026, in San Diego, Calif.

Apr 20, 2026 04:30 AM • globenewswire.com
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the closing of its previously announced underwritten public offering of 87,500,000 shares of its common stock at a price to the public of $2.00 per share. In addition, the underwriters partially exercised their option and purchased 12,700,000 additional shares of common stock. Including the option exercise, the aggregate gross proceeds from this offering were $200.4 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Allogene.

Apr 16, 2026 12:01 PM • globenewswire.com
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the publication of pre-clinical data for ALLO-329 in Nature Communications. ALLO-329 is an investigational allogeneic CAR T product developed specifically for autoimmune diseases.

Apr 15, 2026 04:30 AM • globenewswire.com
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the pricing of an underwritten public offering of 87,500,000 shares of its common stock at a price to the public of $2.00 per share. The gross proceeds from this offering are expected to be $175 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Allogene. The offering is expected to close on or about April 16, 2026, subject to customary closing conditions. In addition, Allogene has granted the underwriters for the offering a 30-day option to purchase up to 13,125,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Apr 14, 2026 05:50 PM • globenewswire.com
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175 million of shares of its common stock. All of the shares are being offered by Allogene. In addition, Allogene intends to grant the underwriters for the offering a 30-day option to purchase up to an additional $26.25 million of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Apr 13, 2026 12:01 PM • globenewswire.com

Price Targets